IGEA Pharma NV
F:3B5
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| NL |
|
IGEA Pharma NV
SIX:IGPH
|
505.5k CHF |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
192B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.6B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.5B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
112.1B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.6B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39.5B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
IGEA Pharma NV
Glance View
IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.
